CSL Behring GmbH (CSL Behring), formerly Aventis Behring GmbH, a subsidiary of CSL Ltd, offers a wide range of healthcare products which is derived from plasma protein biotherapeutics. The company provide products for coagulation disorders, immunoglobulins, chronic inflammatory demyelinating polyneuropathy, hereditary angioedema, haemophilia, alpha1-antitrypsin deficiency and immunodeficiencies. It offers patients different drugs based on plasma, a recombinant factor VIII and a fibrinolytic agent. CSL Behring conducts research in partnership with various academic institutions and organizations to develop plasma and recombinant products. CSL Behring GmbH is headquartered in Marburg, Germany.
You have successfully subscribed and will receive the next available issues